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Summary
Genetic disorders of haemoglobin, particularly the sickle cell diseases and
the alpha and beta thalassaemias, are the commonest inherited disorders
worldwide. The majority of affected births occur in low-income and lower-
middle income countries. Screening programmes are a vital tool to counter
these haemoglobinopathies by: (i) identifying individual carriers and allow-
ing them to make informed reproductive choices, and (ii) generating popu-
lation level gene-frequency estimates, to help ensure the optimal allocation
of public health resources. For both of these functions it is vital that the
screen performed is suitably sensitive. One popular first-stage screening
option to detect carriers of beta thalassaemia in low-income countries is
the One Tube Osmotic Fragility Test (OTOFT). Here we introduce a popu-
lation genetic framework within which to quantify the likely sensitivity and
specificity of the OTOFT in different epidemiological contexts. We demon-
strate that interactions between the carrier states for beta thalassaemia and
alpha thalassaemia, glucose-6-phosphate dehydrogenase deficiency and
Southeast Asian Ovalocytosis have the potential to reduce the sensitivity of
OTOFTs for beta thalassaemia heterozygosity to below 70%. Our results
therefore caution against the widespread application of OTOFTs in regions
where these erythrocyte variants co-occur.
Keywords: thalassaemia, haemoglobinopathies, genetic disorders, epistasis,
screening programmes.
Severe forms of alpha and beta thalassaemia have been esti-
mated to affect approximately 68000 births annually (Modell
& Darlison, 2008; Weatherall, 2010). Individuals who carry
thalassaemic genes are protected against death from malaria
infection (Haldane, 1949; Willcox et al, 1983; Flint et al,
1986; Mockenhaupt et al, 2004; Williams et al, 2005;
Wambua et al, 2006; Taylor et al, 2012); the highest frequen-
cies of thalassaemias are thus found in regions which were
historically malarious (Table I).
Adult haemoglobin (HbA) is a tetramer made up of two
alpha and two beta globin chains. The thalassaemias arise
when production of either alpha or beta globin is
compromised (Weatherall & Clegg, 2001). The vast majority
of alpha thalassaemia is caused by whole gene deletions.
There are two alpha globin genes in tandem on chromosome
16 (HBA1 and HBA2), and it is possible for one or both to
be deleted, leading to four main alpha thalassaemic states.
The loss of a single alpha globin (aa/-a) is phenotypically
silent; the loss of two (-a/-a or aa /--) causes a mild anae-
mia; the loss of 3 (-a/--) causes a variably severe anaemia
called Haemoglobin H disease and the loss of 4 (--/--) is
usually fatal in utero. Beta thalassaemia can be caused by
many different mutations that reduce or eliminate expression
of the beta globin gene (HBB) on chromosome 11. Through-
out this paper we shall use the symbol ‘bT’ to represent a
generic beta thalassaemic mutation. Inheriting a gene for beta
thalassaemia from both parents (bTbT) usually leads to a life-
threatening, transfusion-dependent anaemia (Cooley anae-
mia, or thalassaemia major), whilst heterozygosity (the car-
rier state, bbT) causes only a mild anaemia.
Many of the characteristics of the thalassaemias derive not
only from a limited supply of either alpha or beta globin,
but from the accumulation of unpaired globin chains of the
subunit produced at the normal rate (Weatherall & Clegg,
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2001). If both alpha and beta thalassaemia are inherited
together, there may be an amelioration of symptoms due to
a balancing out of the rate of chain synthesis. This effect can
explain the surprisingly mild course of the disease in some
beta thalassaemia homozygotes (Kan & Nathan, 1970;
Weatherall et al, 1981; Wainscoat et al, 1983), and it has
been noted that such epistasis can make it difficult to detect
carriers of severe thalassaemic mutations (Bowden et al,
1987; Weatherall & Clegg, 2001; Law et al, 2003).
Any programme to identify carriers of beta thalassaemia
involves an initial survey to identify individuals with unusual
red blood cell indices, followed by further analysis of abnor-
mal samples. Table II summarizes some key phenotypic char-
acteristics of alpha and beta thalassaemic individuals. In a
screen for beta thalassaemia heterozygotes, microcytosis or
low cellular haemoglobin levels are typical phenotypic traits
used to distinguish abnormal samples in the first instance.
The presence of elevated levels of Haemoglobin A2 (HbA2)
in those samples is the gold standard used to identify definite
carriers of beta thalassaemia in the second stage of the
screen. Nevertheless, there do exist ‘silent’ beta thalassaemic
mutations with normal HbA2 levels (Weatherall & Clegg,
2001) and there can be problems interpreting samples with
borderline elevated HbA2, so even the gold standard does
not necessarily represent 100% accuracy.
The most reliable method to quantify microcytosis is to use
an automated cell counter. However, a simpler and cheaper
method, used in regions where resources are limited, is to detect
cells with low red blood cell indices using the one tube osmotic
fragility test or OTOFT (Kattamis et al, 1981). The osmotic fra-
gility of a red blood cell is related to its size and shape: the
smaller the cell, the more resistant it should be. Similarly, low
cellular haemoglobin may also be linked to an increase in osmo-
tic resistance. To perform the OTOFT, a drop of blood is placed
in a tube containing buffered NaCl solution (typically 036%
NaCl) or glycerine-saline; the tube is allowed to stand, then the
degree of lysis is assessed photometrically or by visual inspection.
In the latter case the test is known as the Naked Eye Single
Tube Red cell Osmotic Fragility Test or NESTROFT (Raghavan
et al, 1991). If lysis is below a certain level, the sample is
deemed microcytic and should be referred for further testing.
Figure 1A compares reported mean corpuscular volume
(MCV) values of red blood cells from individuals carrying
different combinations of thalassaemic mutations (Sanna
et al, 1980; Kanavakis et al, 1982; Melis et al, 1983; Rosatelli
et al, 1984; Maccioni & Cao, 1985; Weatherall & Clegg,
2001), together with the MCVs of blood samples that tested
either positive or negative in a OTOFT (Yazdani et al, 2008).
The low MCV of carriers of either alpha or beta thalassaemia
can be elevated by the coinheritance of alpha and beta thalas-
saemic mutations, due to the aforementioned ameliorative
effect of balancing out globin chain synthesis, such that the
range of MCV values for a/a bbT individuals overlaps
the range of MCV values that tested negative in the OTOFT.
This suggests there may be a risk of a/a bbT individuals
being missed by the OTOFT screen.
However, the correlation between osmotic fragility and
MCV is not perfect. Despite their increased MCV, the osmo-
tic fragility profile of doubly heterozygous alpha-beta thalas-
saemic cells remains distinct from that of normal cells – as
illustrated in Fig 1B (Maccioni & Cao, 1985). Osmotic fragil-
ity tests may therefore be able to detect properties of thalas-
saemic cells that are unrelated to MCV. Nevertheless, the
osmotic fragility of thalassaemic cells still presents a potential
problem for modern one-tube tests. Maccioni and Cao
(1985) were able to detect the presence of heterozygous beta
thalassaemia, even in the simultaneous presence of alpha
thalassaemia, by applying a OTOFT at 04% NaCl. As can be
seen in Fig 1B, this concentration offers the maximum dis-
criminative power between normal and alpha-beta thalasssae-
mic cell types. However, many modern day OTOFTs are
performed at lower NaCl concentrations (Table III). A test
performed at 036% NaCl may be more prone to missing
some a/aa bbT or a/a bbT samples.
A further difficulty in detecting individuals carrying both
alpha and beta thalassaemia may arise from the variation in
another protein: glucose-6-phosphate dehydrogenase (G6PD)
(Melis et al, 1983). G6PD, encoded by G6PD on the X chro-
Table I. A selection of the highest reported frequencies of alpha and beta thalassaemia.
Methods used Highest frequencies observed
Alpha thalassaemia Exact gene frequencies
determined by DNA analysis
Up to 017 in Pakistan (Khan et al, 2003)
041 on the coast of Kenya (Wambua et al, 2006)
Up to 068 in Oceania (Flint et al, 1986)
Up to 083 in the Tharu population of the Terai region of Nepal
(Modiano et al, 1991)
Alpha thalassaemia trait determined
phenotypically
Up to 037 in Sardinian populations (Cao et al, 2008)
Beta thalassaemia Carrier frequencies determined
phenotypically
Up to 015 in Sardinian villages (Siniscalco et al, 1966)
Up to 011 in Liberia, specifically in members of the Kru tribal group
(Willcox, 1975)
Up to 009 in Gujerat (Patel et al, 2012)
011 in Maewo, Melanasia (Bowden et al, 1987)
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mosome, helps to protect erythrocytes from oxidative damage.
Nucleotide substitutions in G6PD can disrupt the function of
the enzyme, causing G6PD deficiency. G6PD deficiency tends
to increase the MCV of cells from beta thalassaemia heterozyg-
otes, but not to the same extent as alpha thalassaemia. How-
ever, individuals with the a/a bbT genotype who are also
G6PD-deficient may enjoy a further boost to their MCV: these
individuals tended to have the highest MCV values reported by
Melis et al (1983). G6PD deficiency was also suggested by
Maccioni and Cao (1985) as one of the factors that might hide
the presence of beta thalassaemia in OTOFT screens, due to its
MCV-increasing effects.
Finally, a recent case report from Thailand (Fucharoen
et al, 2007) reveals yet another complication for osmotic fra-
gility-based screens for carriers of beta thalassaemia. Fucha-
roen et al (2007) described a Thai female heterozygous for
both beta thalassaemia and Southeast Asian Ovalocytosis
(henceforth SAO, caused by heterozygosity for a deletion in
the Band 3 gene SLC4A1), whose osmotic fragility profile is
entirely normal. It seems that the altered membrane proper-
ties of SAO cells counteract the increased osmotic resistance
that usually results from heterozygous beta thalassaemia. The
authors noted that this masking effect could create a pitfall
for osmotic screening in regions where SAO is common
(Fucharoen et al, 2007).
In this paper, we present an analytical framework to inves-
tigate the sensitivity and specificity of OTOFTs as first-stage
screens for carriers of beta thalassaemia, in the context of
epistasis with alpha thalassaemia, G6PD deficiency and SAO.
Our analysis focuses in particular on three unknown factors:
(i) the probability of OTOFTs detecting carriers of beta thal-
assaemia in the simultaneous presence of homozygosity or
heterozygosity for a common alpha thalassaemic deletion;
(ii) the potential for G6PD deficiency to modify the chances
of double heterozygotes for both alpha and beta thalassaemia
being detected, and (iii) the probability of heterozygosity for
a common alpha thalassaemic deletion causing a false posi-
tive OTOFT result.
We demonstrate that high frequencies of alpha thalassae-
mia combined with G6PD deficiency and SAO have the
potential to reduce the sensitivity of OTOFTs to unaccept-
able levels. Our results underscore the fact that any decision
to roll out OTOFT-based beta thalassaemia screening to a
new population should take account of that population’s
pre-existing genetic background. Our framework offers a
potential tool for guiding such decisions, but also highlights
the need for an improved understanding of the performance
of OTOFTs for different genotypes.
Methods
We considered a population in which alpha thalassaemia is
caused by the deletion of a single alpha globin gene (HBA2
or HBA1) i.e. ‘a’, also designated a+; by far the most
Table II. The phenotypic signatures of thalassaemia traits.
Alpha thalassaemia: aa/a Alpha thalassaemia: a/a
Heterozygous beta
thalassaemia: bbT
Microcytosis: MCV <80 fl 43% of sample had MCV <80 fl
(n = 191)
100% of sample had
MCV <80 fl
(n = 77)
100% of males had MCV <80 fl
100% of females had
MCV <80 fl
(Total n = 83)
Hypochromia: <27 pg Hb
per cell
64% of sample had
MCH <27 pg (n = 184)
100% of sample had
MCH <27 pg (n = 75)
100% of males had MCH <27 pg
100% of females had
MCH <27 pg (Total n = 83)
High RBC count
>57 9 1012/l
(males)
or >5 9 1012/l (females)
31% of males had
RBC >57 9 1012/l
(n = 77)
41% of females had
RBC >5 9 1012/l
(n = 102)
64% of males had
RBC >57 9 1012/l
(n = 30)
73% of females had
RBC >5 9 1012/l
(n = 45)
43% of males had
RBC >57 9 1012/l
58% of females had
RBC >5 9 1012/l
(Total n = 83)
Elevated HbA2: >34% HbA2 levels indistinguishable from
controls with full complement of
HBA1 and HBA2 genes
(Maude et al, 1985)
HbA2 levels indistinguishable from
controls with full complement of
HBA1 and HBA2 genes
(Maude et al, 1985)
100% of sample had
HbA2 >34% (n = 83)
Weatherall and Clegg (2001) provide a complete review of the thalassaemias and their pathophysiology. In Table II, beta thalassaemia statistics
were extrapolated from the means and standard deviations reported by Knox-Macaulay et al (1973) in British thalassaemia heterozygotes, assum-
ing each phenotype to be normally distributed within the sample. MCV, MCH and red cell blood count statistics for alpha thalassaemia were
extrapolated from Table 114 in Weatherall and Clegg (2001) using values reported for 16+ years of age, and similarly assuming normal distribu-
tions. HbA2 levels in alpha thalassaemic individuals are based on a study of alpha thalassaemic children in Jamaica (Maude et al, 1985).
MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; Hb, haemoglobin; RBC red blood cell.
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common type worldwide. Let us represent beta thalassaemic
alleles using the symbol bT; the band 3 deletion with the
symbol rDEL and G6PD-deficient X chromosomes with the
symbol XDEF. There are 81 female genotypes in the popula-
tion, made up of all possible combinations of alpha globin
genotype (aa/aa, a/aa or a/a); beta globin genotype
(bb, bbT, bTbT); SAO genotype (rr, rrDEL, rDELrDEL)
and G6PD genotype (XX, XXDEF, XDEFXDEF). There are,
however, only 54 possible male genotypes because males are
hemizygous for the X chromosome (XY or XDEFY). We
assume that none of the individuals being screened are
homozygous for rDEL, because no individuals homozygous
for the SAO deletion in SLC4A1 have been reported to sur-
vive. We similarly assume that individuals with beta thalas-
saemia major (bTbT) are excluded from thalassaemia
screening programmes, since their illness will have become
apparent in childhood.
In this analysis, a, b, s and c represent the allele frequen-
cies of ‘a’, bT, rDEL and XDEF in the population, and m
represents the proportion of individuals who test positive for
microcytosis in a OTOFT. The latter can be split into two
quantities: the proportion of individuals who are both micr-
ocytic and prove to have elevated HbA2 levels at the next
phase of the screen (m+), and the proportion of individuals
who are microcytic but lack elevated HbA2 (m0). Of the m0
individuals, some will carry alpha thalassaemia. These we
shall designate m0a.
As noted in the introduction, epistasis between alpha and
beta thalassaemia may mean that not all individuals with
both alpha and beta thalassaemia will necessarily test positive
in a OTOFT. To allow for these uncertainties, we introduce
the following parameters: g1, the proportion of non-G6PD-
deficient a/aabbT rr samples that test positive in a
OTOFT; g2, the proportion of non-G6PD-deficient a/a
(A)
(B)
Fig 1. Mean corpuscular volumes (MCVs) and
osmotic fragility profiles for different thalassae-
mic genotypes. In panel (A), bars represent the
mean  1 standard deviation for the MCV of
each indicated genotype; sample sizes are indi-
cated above each bar. Where a sample was sta-
ted to consist only of males or females, this
has been indicated with ‘M’ or ‘F’. Markers
lacking error bars represent reported values
from single individuals of the indicated geno-
type. The ‘normal’ and alpha thalassaemia data
are taken from Table 114 of Weatherall and
Clegg (2001), and are MCV values for individ-
uals >16 years of age. The beta thalassaemic
and alpha-beta thalassaemic data are taken
from Kanavakis et al (1982), Rosatelli et al
(1984), Maccioni and Cao (1985), Sanna et al
(1980) and Melis et al (1983). Sanna et al
(1980) reported MCV values for alpha thalas-
saemic individuals defined phenotypically; we
have assumed this sample to represent homo-
zygotes for ‘a’. The one tube osmotic fragility
test (OTOFT) MCV data are from Yazdani
et al (2008). Panel (B) illustrates haemolysis
rates (y axis) for different concentrations of
NaCl (x axis) for compound alpha-beta thalas-
saemia heterozygotes and normal cells (Macci-
oni & Cao, 1985). No distinction was made in
that study between different forms of alpha
thalassaemia. The Sanna et al data in panel (A)
were extracted from graphs in Sanna et al
(1980) using GetData Graph Digitizer. The
curves in panel (B) were extracted using Get-
Data Graph Digitizer from: Journal of Medical
Genetics, Maccioni, L. & Cao, A., 22, 374–376,
copyright 1985. With permission from BMJ
Publishing Group Ltd.
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bbT rr samples that test positive in a OTOFT and g3, the
proportion of non-G6PD-deficient a/aa bb rr samples
that test positive in a OTOFT.
It is also possible that any OTOFT masking effect of alpha
thalassaemia on beta thalassaemia detection depends on the
simultaneous presence of G6PD deficiency. To allow for
Table III. A selection of field surveys assessing the sensitivity of OTOFTs (including NESTROFT) as a test for beta thalassaemia.
Study Population and location
Sensitivity of
OTOFT
for beta
thalassaemia Testing solution Thalassaemia frequency
Sumera et al (2012) Dow Diagnostics
Research
and Reference
Laboratory in Karachi,
Pakistan
93% 036% NaCl 73/503 subjects had elevated HbA2 levels:
frequency of bT = 007
Mamtani et al (2006,
2007)
Sindhi individuals living
in Nagpur, India
934%, 91% 036% NaCl Jawahirani et al (2007) studied the same
population, and reported sub-population beta
thalassaemia frequency estimates of bT = 008
–02
Chakrabarti et al
(2012)
Pregnant Rajbanshi
women in West Bengal
95% 036% NaCl 17/500 subjects had elevated HbA2 levels:
frequency of bT = 0017
Manglani et al (1997) Field camps in Gujarat
and Maharashtra
944% 036% NaCl 142/830 subjects had elevated HbA2 levels:
frequency of bT = 0085
Wiwanitkit et al
(2002)
Pregnant Thai women 100% 036% NaCl 3/213 had beta thalassaemia trait: frequency of
bT = 0007
1/213 had ‘alpha thalassaemia trait confirmed
by genotyping’
Sirichotiyakul et al
(2004)
Maharaj Nakorn Chiang
Mai, 446 singleton
pregnancies (2002)
976% 045% glycerine
saline solution
14/446 had elevated HbA2: frequency of
bT = 0016
33/446 had positive result for the SEA alpha
thalassaemic deletion (a double deletion of
alpha globin); frequency of SEA
deletion = 0037
Tongprasert et al
(2010)
Maharaj Nakorn, Chiang
Mai, 477 singleton
pregnancies, (2002–
2008)
100% (for both beta
thalassaemia and
heterozygosity for
the SEA deletion)
045% glycerine
saline solution
28/417 had elevated HbA2: frequency of
bT = 0034. 33/417 had positive result for the
SEA alpha thalassaemic deletion; frequency of
SEA deletion = 0040.
Mehta (2002) Lohana community 98% sensitivity 036% NaCl 49/450 had elevated HbA2 (decision to test for
HbA2 seems to have been partly based on
NESTROFT result, so this is perhaps not a
true population estimate): frequency of
bT = 0054
Mehta (2002) Antenatal clinics 100% sensitivity 036% NaCl 68/2350 had elevated HbA2 (decision to test
for HbA2 seems to have been partly based on
NESTROFT result, so this is perhaps not a
true population estimate): frequency of
bT = 0015
El-Beshlawy et al
(2007)
Siblings of hospital
patients (children),
families had no history
of haematological
disease
87% sensitivity 036% NaCl 90/1000 had unambiguously elevated HbA2,
giving a frequency of bT of 0045. If
borderline elevated HbA2 samples are also
assumed to carry beta thalassaemia, the
frequency of bT in the sample is 0051
Table III only includes population surveys where nothing was known about the thalassaemia status of participants prior to their recruitment, and
where it is possible to assess the likely population frequency of beta thalassaemia from information given in the paper. Other studies have assessed
the sensitivity of OTOFTs by specifically targeting individuals already known to have beta thalassaemia (or the families of individuals already
known to have thalassaemia major). Such surveys typically report very high sensitivity values (Thomas et al, 1996; Bobhate et al, 2002) but, as
noted by Mamtani et al (2006), are likely to overestimate sensitivities by including such a high frequency of samples that are extremely likely to
be positive. OTOFT, one tube osmotic fragility test; NESTROFT, naked eye single tube red cell osmotic fragility test.
Interacting Malaria Protective Mutations Confound Screens
ª 2014 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. 121
British Journal of Haematology 2015, 169, 117–128
this, we shall also introduce parameters g4: the proportion of
a/aabbT rr XDEFXDEF females or a/aabbT rr XDEFY
males to test positive in a OTOFT, and g5: the proportion of
a/abbT rr XDEFXDEF females or a/abbT rrXDEFY
males to test positive in a OTOFT.
We shall assume that the coinheritance of SAO alongside
either alpha or beta thalassaemia eliminates the osmotic
resistance of each, leading to a negative OTOFT result. There
is evidence that this occurs for beta thalassaemia (Fucharoen
et al, 2007); the osmotic resistance of cells with both alpha
thalassaemia and SAO has not been tested.
Finally, thalassaemia is not the only condition that
could give rise to microcytosis, and hence positive results
in a field microcytosis test. Iron deficiency anaemia
(typically caused by poor nutrition, or intestinal parasites)
is extremely common in many of the regions where thalas-
saemia is also found, and can also lead to smaller than
usual red blood cells. The parameter d represents the
proportion of the sample with non-genetic causes of a
positive OTOFT.
Eqs 1–4 show how m+(i); m0a and m0 are calculated. m+(i)
will be different for males and females, so we present two
different equations, using (1) for females and (2) for males.
m+(i) and m0(i) are equal to the number of true positives and
false positives for beta thalassaemia in the sample. Eqs 5–7
give the numbers of false negatives (nf(i)) and true negatives
(nt(i)), and finally Eqs 8 and 9 calculate the sensitivity and
specificity of a OTOFT-like test for beta thalassaemia.
mþð1Þ ¼
ð1 sÞ2 ðð1 cÞ2 þ 2cð1 cÞÞf1 þ c2f2
 
ð1 b2  s2 þ b2s2Þ ð1Þ
where
f1 = 2(1  a)2b(1  b) + g14a(1  a)b(1  b) + g22a2b(1  b)
f2 = 2(1  a)2b(1  b) + g44a(1  a)b(1  b) + g52a2b(1  b)
mþð2Þ ¼ ð1 sÞ
2 ð1 cÞf1 þ cf2ð Þ
ð1 b2  s2 þ b2s2Þ ð2Þ
where f1 and f2 are defined as for Eq. 2.
m0a ¼
ð1 sÞ2 a2ð1 bÞ2 þ 2g3að1 aÞð1 bÞ2
 
ð1 b2  s2 þ b2s2Þ ð3Þ
m0ðiÞ ¼ m0a þ ð1mþðiÞ m0aÞd ð4Þ
nf ð1Þ ¼
ð1 sÞ2 ðð1 cÞ2 þ 2cð1 cÞÞf3 þ c2f4
 þ 4sð1 sÞbð1 bÞ
ð1 b2  s2 þ b2s2Þ
ð5Þ
where
f3 = (1  g1)4a(1  a)b(1  b) + (1  g2)2a2b(1  b)
f4 = (1  g4)4a(1  a)b(1  b) + (1  g5)2a2b(1  b)
nf ð2Þ ¼ ð1 sÞ
2 ð1 cÞf3 þ cf4ð Þ þ 4sð1 sÞbð1 bÞ
ð1 b2  s2 þ b2s2Þ ð6Þ
where f3 and f4 are defined as for Eq. 5.
ntðiÞ ¼ 1 mþðiÞ þm0ðiÞ þ nf ðiÞ
  ð7Þ
sensitivityðiÞ ¼ mþðiÞ
mþðiÞ þ nf ðiÞ
ð8Þ
specificityðiÞ ¼ ntðiÞ
ntðiÞ þm0ðiÞ
ð9Þ
Results
Increasing frequencies of alpha thalassaemia and G6PD
can reduce the sensitivity of OTOFTs for beta
thalassaemia
Sensitivity measures the reliability with which a negative
test result indicates the absence of an underlying condi-
tion. Highly sensitive tests are crucial when offering genetic
counselling. From the equations given in the Methods, the
critical factors determining the sensitivity of OTOFTs are
(i) the frequencies of SAO, alpha thalassaemia and G6PD
deficiency in the population and (ii) the values of g1, g2,
g4 and g5.
We shall first examine the potential impact of alpha thal-
assaemia alone on OTOFT sensitivity. Whenever it is possible
for alpha thalassaemia to mask the presence of heterozygous
beta thalassaemia, there is a decline in sensitivity with
increasing alpha thalassaemia frequency (Fig 2). In the sur-
face described in Fig 2A, heterozygosity for a single alpha
globin deletion (a/aa) does not mask the detection of beta
thalassaemia carriers by a OTOFT, hence g1 = 1, but homo-
zygosity for a single alpha globin deletion (a/a) can. As
the masking effect of a/a increases there is a striking
non-linear decline in sensitivity with increasing alpha thalas-
saemia frequency. The surface illustrated in Fig 2B describes
a more extreme situation, where homozygosity for a single
alpha globin deletion always masks the detection of heterozy-
gous beta thalassaemia (g2 = 0), and a/aa can simulta-
neously have a masking effect. As the masking effect of a/
aa increases, the decline in sensitivity with increasing alpha
thalassaemia frequency becomes more linear – and therefore
lower frequencies of alpha thalassaemia could potentially
have a bigger impact on sensitivity.
However, as we saw in Fig 1B, complete masking of beta
thalassaemia carriers by the simultaneous presence of alpha
thalassaemia (i.e. g2 = 0) seems unlikely – there remains a
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difference in osmotic fragility between doubly heterozygous
alpha-beta thalassaemic cells and normal cells. What if, as
suggested in the introduction, it is a combination of alpha
thalassaemia and G6PD deficiency which has the most pow-
erful masking effect?
As shown in Fig 3, even if the masking effect of alpha
thalassaemia alone is relatively minor (g1 = 095; g2 = 075),
an additional masking effect experienced only by those who
inherit alpha thalassemia, heterozygous beta thalassaemia and
G6PD deficiency could have a significant impact on the sen-
sitivity of OTOFTs. Figure 3 assumes that G6PD-deficient
a/abbT individuals always test negative in a OTOFT, and
illustrates the effect of varying g4: the probability of G6PD-
deficient a/aabbT individuals testing positive. In a popula-
tion where the frequency of G6PD-deficient X chromosomes
is 15% and the frequency of an ‘a’ alpha thalassaemic dele-
tion is 025 (both perfectly plausible in malaria-endemic
regions), if g4 ≤04 then OTOFT sensitivity in males drops
below 93%.
A combination of alpha thalassaemia, G6PD deficiency
and SAO could reduce the sensitivity of OTOFTs to
<70%
In Papua New Guinea, reported SAO frequencies range from
00005 to 0074 (Patel et al, 2004); in Sumba Island, Indonesia,
an SAO frequency of 0057 has been reported (Shimizu et al,
2005). Even if SAO heterozygosity completely masks the osmo-
tic fragility of beta thalassaemia carriers, such SAO frequencies
alone will only reduce the sensitivity of OTOFTs as a test for
beta thalassaemia to between 08 and 09 (Fig 4).
However, populations in Papua New Guinea also carry
some of the highest frequencies of alpha thalassaemia in the
world, e.g. 068 in northern coastal populations (Flint et al,
1986). Furthermore, G6PD deficiency in populations in this
region can reach 15% (Howes et al, 2012). If we assume that
alpha thalassaemia has a small masking effect on the presence
of heterozygous beta thalassaemia (g1 = 095, g2 = 075), but
that this masking is exacerbated by the coinheritance of G6PD
deficiency (g4 = 05, g5 = 0), the combined effect of alpha thal-
assaemia, SAO and G6PD deficiency is to reduce OTOFT sen-
sitivity dramatically (Fig 4). With an alpha thalassaemia
frequency of 068; SAO frequency of 007, and G6PD deficient
X chromosome frequency of 0.13, all entirely plausible for the
Madang region of Papua New Guinea (Flint et al, 1986; Brabin
& Brabin, 1990; Patel et al, 2004), the sensitivity of the OTOFT
for beta thalassaemia drops to 0.74 in females and 0.69 in
males (Fig 4 marker A). Reported beta thalassaemia carrier fre-
quencies in coastal Papua New Guinea reach up to 25% (Hill
et al, 1988). The reported beta thalassaemia carrier frequency
in Kar Kar Island, just a few kilometres off the coast from the
high SAO/high alpha thalassaemia region of Madang, is 115%.
Any attempt at OTOFT-based screening in these populations
would be a matter of concern.
Certain regions of Indonesia may also present a problem
due to the combination of SAO and alpha thalassaemia.
Marker B in Fig 4 pinpoints plausible population frequencies
of SAO and alpha thalassaemia for Sumba Island, which has
also been reported to possess a G6PD deficiency frequency of
8% (Shimizu et al, 2005). Although the sensitivity of the OT-
OFT predicted within our framework under these circum-
stances is higher, at 0.89 in females and 0.88 in males, it is
still far from ideal. Furthermore, the alpha thalassaemia fre-
quency we use for marker B (005), is consistent with the
11% and 10% carrier frequencies for alpha thalassaemia
reported by Setianingsih et al (2003) in South Sulawesi and
South Sumatera respectively, but alpha thalassaemia surveys
specific to Sumba island are lacking. The true Sumba Island
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frequency of alpha thalassaemia may well be higher, given
the history of high malaria transmission in the area.
Alpha thalassaemia may have a more profound effect on
the specificity of OTOFTs than iron deficiency
The specificity of a test is the reliability with which a positive
test outcome indicates the presence of an underlying
condition. In the case of beta thalassaemia, if a first-stage
test is insufficiently specific, a great many samples from non-
carriers may be sent for further testing. If medical budgets
are limited, this may place an unacceptable strain on
resources.
Regardless of epistasis between alpha and beta thalassae-
mia, or any effect of SAO or G6PD, the fact that the a/a
bb genotype leads to microcytosis means that there is likely
to be a negative correlation between alpha thalassaemia
frequency and OTOFT specificity for carriers of beta thalas-
saemia (Fig 5). However, if heterozygosity for a single alpha
thalassaemic deletion (a/aa bb) can also lead to microcyto-
sis and a positive OTOFT, a probability represented here by
the parameter g3, the relationship between alpha thalassaemia
and OTOFT specificity declines more steeply as g3 becomes
larger (Fig 5).
A second factor that will affect the specificity of OTOFTs
for carriers of beta thalassaemia is the level of iron defi-
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ciency in the population, represented by parameter d, the
proportion of the population with a non-genetic cause of a
positive OTOFT. Sumera et al (2012) showed that in a sur-
vey of 503 individuals, 174 were iron-deficient (determined
by serum ferritin levels) and of those, 13% were OTOFT-
positive. Using these values we might estimate d = 005
(013 9 035). The study reported by Sumera et al (2012)
was carried out in Pakistan, presumably on adults. A study
of children in Egypt (El-Beshlawy et al, 2007) found that
310 out of 1000 individuals were iron-deficient (low serum
iron, low transferrin saturation and normal to high total
iron-binding capacity) and of those, 639% tested positive
in a OTOFT. Based on these values, we might estimate
d = 02 (031 9 064). The red and blue dotted lines in
Fig 5 indicate the effect of these two values of d on the
specificity of the test when g3 = 0. For a screening pro-
gramme carried out among the population in Pakistan stud-
ied by Sumera et al (2012), alpha thalassaemia is likely to
cause greater losses in specificity than iron deficiency alone
(red line) when g3 >0. In a population such as that studied
by El-Beshlawy et al (2007), iron deficiency alone already
dramatically reduces the specificity of the test (blue line),
but any additional effect of alpha thalassaemia will com-
pound the problem.
Discussion
Reliable methods of genetic screening are vital in regions
where beta thalassaemia is common. A spate of recent studies
(see Table III) have highlighted OTOFTs as sensitive, low-
cost tests for beta thalassaemia heterozygosity, which can be
carried out in virtually any setting. Despite these promising
results, the analyses we present here caution against the large
scale application of OTOFTs, due to the potential for epista-
sis between beta thalassaemia and other red blood cell vari-
ants to reduce the tests’ sensitivity.
All of the variants considered here: alpha thalassaemia,
beta thalassaemia, G6PD deficiency and SAO, have malaria-
protective properties (Williams, 2006), and therefore have
distributions that are correlated with malaria exposure. If
epistasis between these traits introduces any kind of system-
atic bias against accurate test results, such a problem is likely
to be at its worst in areas with a history of high malaria
exposure, where beta thalassaemia screening is most needed.
Table III illustrates that the populations with the lowest OT-
OFT sensitivity are those with relatively high frequencies of
beta thalassaemia.
Our analysis highlights important gaps in our understand-
ing of OTOFTs. We introduced the parameters g1, g2 and g3,
to represent respectively, the probabilities of a/aabbT rr;
a/abbT rr and a/aa bb rr samples with normal
G6PD activity testing positive, and g4 and g5 to take into
account the possibility that G6PD deficiency may change the
probability of a/aabbT rr and a/abbT rr testing
positive. As illustrated in Figs 2, 3 and 5, selecting different
values for these parameters has a huge effect on the predicted
sensitivity and specificity of OTOFTs. However, as yet, we
have no reliable estimates for these individual values, and
how they change with the concentration of NaCl used in the
test. Reliable estimates for g1 – g5, at different NaCl concen-
trations, and for different beta thalassaemic mutations would
allow us to predict the likely specificity and sensitivity of
OTOTFs with a higher degree of confidence, and may even
make it possible to tailor the recommended NaCl concentra-
tion for the test according to the genetic background of the
population. However, maintaining a very specific NaCl
concentration in the field is already problematic.
To date, only one case report (Fucharoen et al, 2007) has
studied the osmotic fragility profile of red blood cells from
an individual heterozygous for both beta thalassaemia and
SAO, demonstrating the potential for SAO to mask the
osmotic resistance characteristic of beta thalassaemia carriers.
Further study is clearly needed in this area. The model
results we present here are arguably a worst-case scenario
because it may not be that all beta thalassaemia heterozyg-
otes who co-inherit SAO end up with a normal osmotic fra-
gility profile. On the other hand, it is known that red blood
cell membrane disorders in general have a tendency to
increase the osmotic fragility of red blood cells (Da Costa
et al, 2013). Other erythrocyte membrane abnormalities may,
therefore, also counteract the osmotic resistance of cells from
beta thalassaemia carriers. Although the variants responsible
for other membrane abnormalities do not attain the same
high frequencies as SAO in southeast Asia, their potential to
Sp
ec
ifi
ci
ty
Frequency of “- α” deletion
0 0·05 0·1 0·15 0·2 0·25 0·3 0·35 0·4
0·55
0·6
0·65
0·7
0·75
0·8
0·85
0·9
0·95
1
g3 = 0
g3 = 0·25
g3 = 0·5
Fig 5. The effects of iron deficiency and alpha thalassaemia levels on
the specificity of one tube osmotic fragility tests for beta thalassae-
mia. Parameter values were as follows: g1 = 1, g2 = 1; beta thalassae-
mia frequency = 012; SAO frequency = 0; G6PD frequency = 0.
Different values of g3 are indicated by the different line styles: g3 = 0
(. . .); g3 = 025 (solid lines) and g3 = 05 (—). Different values of d
are indicated by the different coloured lines: d = 0 (black), d = 005
(red) and d = 02 (blue).
Interacting Malaria Protective Mutations Confound Screens
ª 2014 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. 125
British Journal of Haematology 2015, 169, 117–128
hide carriers of beta thalassaemia may still be a cause for
concern.
We considered one environmental factor: iron deficiency.
However, we have not yet explored the possibility for other
deficiencies, e.g. vitamin B12, to affect the sensitivity of OT-
OFTs by increasing the MCV of beta thalassaemia heterozyg-
otes (Bilic et al, 2004). This would be an important addition
to future work.
Other clinically important haemoglobinopathies - particu-
larly sickle cell trait or haemoglobin C – exist alongside beta
thalassaemia in many malarious or former malarious zones.
Carriers of sickle cell trait or haemoglobin C have normal
osmotic fragility, thus will be completely missed by screens
that rely on OTOFTs alone as a first step. As reviewed by Gi-
ordano (2013), a truly effective screening programme any-
where in the world should now include a complete blood
count, tests to examine red cell morphology, and either high
performance liquid chromatography (HPLC) or capillary
electrophoresis to separate and quantify the various haemo-
globins in a sample. Such screening programmes would pick
up carriers of beta thalassaemia without the need for OT-
OFTs.
However, the very reason OTOFTs are attractive is that
tests such as those just described are expensive. Certain older
electrophoretic or chromatographic methods to quantify
HbA2 are reliable and much cheaper than modern HPLC
(Weatherall & Clegg, 2001), so there may be a middle
ground to be found, where accuracy is not sacrificed for the
sake of cost. But, if absolutely the only economically viable
option, are beta thalassaemia screens using OTOFTs still bet-
ter than nothing? The studies summarized in Table III dem-
onstrate that sensitivities of over 90% are possible in specific
populations, and the authors of these studies have suggested
OTOFTs have the potential to be useful tools in those set-
tings. But if this approach is to be established elsewhere it
will need prior assessment of the levels of at least alpha thal-
assaemia and G6PD deficiency in the population to be stud-
ied. Like all haemoglobin variants, these conditions occur at
different frequencies in various parts of high frequency popu-
lations, and therefore micro-mapping of many centres is
required. Unfortunately, the diagnosis of carriers of alpha
thalassaemia (i.e. aa/a; a/a or aa/ genotypes) can
only be reliably accomplished by DNA analysis. In countries
where facilities for this are not available they will have to
form partnerships, either with rich countries (north/south
partnerships) or with adjacent poorer countries where these
techniques have been recently developed (south/south part-
nerships). The approaches to developing these partnerships
has been clearly defined by the World Health Organization
(WHO, 2002).
As we have shown here, in some populations, the sensitiv-
ity of the OTOFT for carriers of beta thalassaemia may drop
below 70%. There must come a point at which a test is
deemed too insensitive for widespread use. If nothing else,
the results shown here are a strong argument for population-
specific pilot studies in any regions where OTOFT-based
screening is proposed. The health authorities in question
should decide on an acceptable level of sensitivity before the
pilot study begins.
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